ASX:EYE

Nova Eye Medical (EYE) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
1.23%
Price Target
N/A
EYE stock logo

About Nova Eye Medical Stock (ASX:EYE)

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

EYE Stock News Headlines

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
See More Headlines
Receive EYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nova Eye Medical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
12,792
Year Founded
N/A

Profitability

Net Income
$-14,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$18.77 million
Book Value
A$0.09 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.93
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Victor Previn B.E. (Age 66)
    B.Eng, Founder & Executive Chairman
    Comp: $236.84k
  • Mr. Thomas H. Spurling AM (Age 62)
    BSc (Hons), FRACI, FTSE, Ph.D., MD & Executive Director
    Comp: $252.55k
  • Liam Cook
    Chief Financial Officer
  • Mr. Keith Byrne
    Vice President of Global Operations
  • Mark Flynn
    Investor Relations
  • Ms. Kate Hunt
    Head of Marketing
  • Dr. David Lubeck M.D.
    Chief Medical Officer
  • Mr. Joaquin V. Wolff (Age 66)
    President of Ellex iTrack
  • Ms. Kimberley Menzies
    Group Financial Controller & Global Finance Manager
  • Mr. Simon Jeremy Newton Gray BEc (Age 65)
    C.A., CA, Company Secretary

This page (ASX:EYE) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners